Skip to content
OpenCapital
Get started

Innoviva, Inc. INVA Xacduro — Revenue

Similar metrics at other companies

UroGen Pharma logo
URGNZusduri — Revenue
$29.25M—
Lantheus Holdings logo
LNTHProduct — Revenue
$369.85M+0.8%
Jazz Pharmaceuticals logo
JAZZXywav — Revenue from Contract with Customer, Excluding Assessed Tax
$408.2M+18.4%
PTC Therapeutics logo
PTCTProduct — Revenue
$225.57M+47.0%
LQD
LQDAProduct — Revenue
$129.88M—
Kiniksa Pharmaceuticals International, plc logo
KNSAProduct — Revenue
$214.27M+55.5%

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B—
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K—
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.41B+9.7%
P/E3.5×—
P/S4.2×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%—
Debt / equity0.2×—
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s xacduro — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s xacduro — revenue?
Innoviva, Inc. (INVA) reported xacduro — revenue of $18.07M in Q1 2026.
How has Innoviva, Inc.'s xacduro — revenue changed year-over-year?
Innoviva, Inc.'s xacduro — revenue increased by 132.2% year-over-year, from $7.78M to $18.07M.
What does xacduro — revenue mean?
This metric represents the total revenue generated from the sale of the Xacduro product to customers, excluding any sales-based taxes collected. It serves as a primary indicator of the product's market adoption and commercial performance within the company's infectious disease portfolio. Tracking this figure allows investors to assess the direct top-line contribution and growth trajectory of this specific therapeutic asset.